Polypill Products Market Size (2024 - 2029)

Polypill Products Market Analysis

The Polypill Products Market size is estimated at USD 32.80 billion in 2024, and is expected to reach USD 36.20 billion by 2029, growing at a CAGR of 2% during the forecast period (2024-2029).

COVID-19 had an indirect impact on the polypill products market. The strict lockdowns and government regulations intended to slow the spread of COVID-19 resulted in decreased product demand across product segments. The COVID-19 virus primarily affected the lungs, causing severe acute respiratory distress syndrome. It was later observed that it also affected other organs, including the heart. Cardiovascular complications associated with COVID-19 were comprehensive and included cardiac injury, arrhythmia, and heart failure. A study by the National Health Commission of China 2021 reported that some patients presented primarily cardiovascular symptoms, such as palpitations and chest tightness, rather than respiratory symptoms during the initial occurrence of COVID-19. The secondary impact of COVID-19 on patient’s cardiovascular systems increased the demand for its treatment; however, the demand for the polypill increased during the pandemic. According to guidelines issued by the Medical Associations during the pandemic in 2021, cardiac treatments for COVID-19-affected patients included standard heart failure therapies, steroid-based drugs, anticoagulation treatments, aspirin to prevent microclots, and, if required, cardiac surgery. Thus, the demand for the polypill during the COVID-19 pandemic remained unpredictable due to the lack of research studies on the use of a polypill on COVID-19-diagnosed patients with cardiovascular disorders.

The polypill is a pill that has a combination of several drugs commonly used to treat heart disease and high blood pressure. The polypill is a safe, effective, and usable strategy to improve compliance in people at risk of cardiovascular disease (CVD). Some of the significant advantages of polypill that are expected to boost the adoption of polypill products during the forecast period include the cost-effective pill, combination of multiple drugs in one dosage form, high adherence among the elderly population, and a rise in utilization of polypill products. One of the major advantages of polypill products over other formulations is lower dosages of different medications, which, in turn, are projected to reduce the side effects. The key players apply several marketing strategies to increase their market presence and share. For instance, key players are planning to promote polypill products as easy-to-remember medicament and convenient as the USP to improve company sales. Moreover, polypill has also emerged as a low-cost medication alternative and is likely to replace therapies that require multiple medications. In August 2023, the WHO contained three fixed-dose combinations of polypills on its revised Model Lists of Essential Medicines (EML) 2023 for primary and secondary precluding atherosclerotic cardiovascular diseases.

The rising prevalence of CVD globally is driving the polypill market growth rate as polypill is proven to be an effective medication for CVD treatment. For instance, in December 2022, the American Heart Association, Inc. published that 244.1 million people lived with ischemic heart disease (IHD) globally, and the global prevalence of heart stroke in 2020 was 89.1 million people, whereas that of ischemic stroke was 68.2 million, that of intracerebral hemorrhage was 18.9 million, and that of subarachnoid hemorrhage was 8.1 million.

Polypill is a fixed-dose combination used in the treatment of various chronic diseases. This combination of pharmacotherapy can decrease the incidence and prevalence of cardiovascular and other diseases. The cost of product and treatment is a significant factor influencing treatment selection. Therefore, the low cost of polypill products is boosting adoption.

The ramification of polypill ingestion in patients is expected to hamper the market growth during the forecast period. The medication dosages are difficult to adjust in a polypill prescription; due to this, the side effects observed in the patients are cough, muscle aches, and stomach irritation.

Polypill Products Industry Segmentation

As per the scope of the report, polypill products are a fixed-dose combination of several other combinations of drugs targeting different parameters of the disease.

The polypill products market is segmented by type (single-parameter polypill, multi-parameter polypill), application (cardiovascular, diabetes mellitus, other applications), distribution channel (online pharmacies, hospital pharmacies, retail pharmacies), and geography (North America, Europe, Asia-Pacific, Middle East, Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.

The report offers the value (in USD) for the above segments.